Today, Wells Fargo & Company MN Boosts Stake in Fresenius Medical Care AG (FMS)

Today, Wells Fargo & Company MN Boosts Stake in Fresenius Medical Care AG (FMS)
Wells Fargo & Company MN increased its stake in Fresenius Medical Care AG (NYSE:FMS) by 3.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 399,362 shares of the company’s stock after buying an additional 14,254 shares during the period. Wells Fargo & Company MN owned about 0.07% of Fresenius Medical Care AG worth $17,480,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in FMS. Harding Loevner LP raised its stake in shares of Fresenius Medical Care AG by 40.8% in the third quarter. Harding Loevner LP now owns 3,332,640 shares of the company’s stock valued at $145,870,000 after buying an additional 966,390 shares in the last quarter. Cambiar Investors LLC raised its stake in shares of Fresenius Medical Care AG by 2.1% in the third quarter. Cambiar Investors LLC now owns 2,383,684 shares of the company’s stock valued at $104,334,000 after buying an additional 49,951 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Fresenius Medical Care AG by 23.2% in the first quarter. Royal Bank of Canada now owns 529,505 shares of the company’s stock valued at $23,340,000 after buying an additional 99,742 shares in the last quarter. Johnston Asset Management LLC raised its stake in shares of Fresenius Medical Care AG by 4.4% in the third quarter. Johnston Asset Management LLC now owns 355,976 shares of the company’s stock valued at $15,581,000 after buying an additional 14,890 shares in the last quarter. Finally, Manning & Napier Advisors LLC raised its stake in shares of Fresenius Medical Care AG by 9.2% in the third quarter. Manning & Napier Advisors LLC now owns 338,470 shares of the company’s stock valued at $14,814,000 after buying an additional 28,410 shares in the last quarter. 2.50% of the stock is currently owned by institutional investors and hedge funds.

Shares of Fresenius Medical Care AG (NYSE:FMS) traded up 2.60% during trading on Friday, reaching $39.44. 109,581 shares of the company traded hands. Fresenius Medical Care AG has a 52 week low of $38.05 and a 52 week high of $47.52. The company’s 50-day moving average price is $40.59 and its 200-day moving average price is $43.01. The company has a market capitalization of $24.15 billion, a P/E ratio of 20.60 and a beta of 0.58.

Fresenius Medical Care AG (NYSE:FMS) last announced its quarterly earnings results on Thursday, October 27th. The company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.57. The firm had revenue of $4.60 billion for the quarter, compared to the consensus estimate of $4.55 billion. Fresenius Medical Care AG had a net margin of 6.67% and a return on equity of 10.56%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.93 EPS. Equities research analysts forecast that Fresenius Medical Care AG will post $2.02 EPS for the current fiscal year.

FMS has been the topic of several research reports. DZ Bank AG reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a research report on Thursday, November 17th. RBC Capital Markets reaffirmed a “sector perform” rating and issued a $44.00 price objective (up previously from $41.00) on shares of Fresenius Medical Care AG in a research report on Tuesday, November 1st. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a research report on Wednesday, September 21st. HSBC reaffirmed a “hold” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, October 18th. Finally, SunTrust Banks Inc. set a $48.00 price target on shares of Fresenius Medical Care AG and gave the company a “buy” rating in a research report on Thursday, October 13th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $45.33.

Fresenius Medical Care AG Company Profile

Related posts

Leave a Comment